全文获取类型
收费全文 | 968篇 |
免费 | 75篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 60篇 |
妇产科学 | 8篇 |
基础医学 | 88篇 |
口腔科学 | 29篇 |
临床医学 | 166篇 |
内科学 | 213篇 |
皮肤病学 | 17篇 |
神经病学 | 31篇 |
特种医学 | 243篇 |
外科学 | 57篇 |
综合类 | 21篇 |
预防医学 | 36篇 |
眼科学 | 7篇 |
药学 | 33篇 |
中国医学 | 5篇 |
肿瘤学 | 33篇 |
出版年
2024年 | 3篇 |
2023年 | 8篇 |
2022年 | 2篇 |
2021年 | 9篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 22篇 |
2017年 | 12篇 |
2016年 | 19篇 |
2015年 | 22篇 |
2014年 | 26篇 |
2013年 | 24篇 |
2012年 | 19篇 |
2011年 | 19篇 |
2010年 | 38篇 |
2009年 | 56篇 |
2008年 | 28篇 |
2007年 | 12篇 |
2006年 | 14篇 |
2005年 | 7篇 |
2004年 | 9篇 |
2003年 | 14篇 |
2002年 | 11篇 |
2001年 | 13篇 |
2000年 | 11篇 |
1999年 | 15篇 |
1998年 | 54篇 |
1997年 | 54篇 |
1996年 | 64篇 |
1995年 | 48篇 |
1994年 | 45篇 |
1993年 | 47篇 |
1992年 | 18篇 |
1991年 | 11篇 |
1990年 | 17篇 |
1989年 | 34篇 |
1988年 | 33篇 |
1987年 | 32篇 |
1986年 | 33篇 |
1985年 | 23篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 22篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 12篇 |
1976年 | 12篇 |
1975年 | 13篇 |
排序方式: 共有1050条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Results of the Ross operation in a pediatric population 总被引:1,自引:0,他引:1
Mark G. Hazekamp Heynric B. Grotenhuis Paul H. Schoof Marie E.B. Rijlaarsdam Jaap Ottenkamp Robert A.E. Dion 《European journal of cardio-thoracic surgery》2005,27(6):975-979
Objective: To analyse the results of the mid-term clinical and echocardiographic follow-up of the pediatric Ross operation. Methods: Echo-Doppler follow-up of 53 consecutive pediatric Ross procedures performed between 1994 and 2003. Median age was 9.7 years at time of operation (2 weeks–17.7 years). Six patients were younger than 3 months. Median age at follow-up was 15.6 years. Aortic valve/left ventricular outflow tract (LVOT) anomalies were congenital in 49 (92%). Seventy percent had previous surgery or balloon valvuloplasty. Root replacement was used in all. Thirteen patients (25%) had LVOT enlargement. Mean cross-clamp time was 113 (69–189) minutes. Results: Early mortality occurred in 3 patients after emergency surgery following balloon failure (n=1) and extended Ross following interrupted arch/VSD repair (n=2). Late mortality was due to LV fibroelastosis in 2 patients and complicated pulmonary artery stenting in another. RVOT reoperations were required because of late homograft obstruction in 2 patients and because of pulmonary artery stenosis in another. Five patients (9.4%) were reoperated for pulmonary autograft dilatation (n=3) and for leaflet fibrosis or perforation (n=2). Autografts were repaired in two patients, while a mechanical valve was inserted in 3 cases. At 9 years the actuarial survival and event free survival were 89 and 74%, respectively. At last follow-up 90% of autograft diameters indexed to body surface area was above the 90th percentile of normal aortic root diameters. LVOT and RVOT gradients were low and autograft insufficiency was trivial to mild in 84% and mild to moderate in 16%. Autograft stenosis was not noticed. Conclusions: The pediatric Ross procedure remains an important tool but autograft dilatation also occurs in the pediatric population. The significance of this finding has yet to be determined. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.